Latest News

(UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial1 was based on patients with a predominantly clear cell component. Current data on the clinical activity […]

(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. Prior to the publication of TAX-327, there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen […]

(UroToday.com) Following presentations by Dr. Ghadjar assessing dose-intensification among patients receiving salvage radiotherapy following radical prostatectomy and by Dr. Tward looking at the clinical cell-cycle risk score to identify men who can forgo androgen deprivation therapy at the time of dose-escalated radiotherapy for prostate cancer, Dr. Valicenti provided a discussion of these data in the Oral Abstract Session: Prostate Cancer […]

(UroToday.com) Immune checkpoint inhibition has greatly improved clinical outcomes for patients with metastatic urothelial carcinoma and other cancers. Immune checkpoint inhibitors are associated with a class of adverse events, deemed immune-related adverse events due to immune activation. Nonetheless, biomarkers associated with immune-related adverse events are still lacking. Furthermore, high tumor mutational burden has been associated with […]

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, there […]

(UroToday.com) Radiotherapy is a standard treatment for patients with localized prostate cancer. For patients with intermediate and high-risk disease, concurrent androgen deprivation therapy is commonly co-administered. However, there is an existing need to provide prognostication within this group of patients to allow for both treatment intensification and de-intensification. To this end, in a study presented during the […]

(UroToday.com) Prostate cancer diagnosis is predicated on needle biopsy. Histopathologic examination of prostate biopsy specimens is both necessary for diagnosis and to risk-stratify patients with prostate cancer, based on assessment of tumor grade and volume. Despite the key role in assessment of prostate biopsies to guide treatment decision making, there are considerable limitations in the accuracy […]

(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussion from Dr. Arlene Siefker-Radtke discussing “Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma” and “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or […]

(UroToday.com) External beam radiotherapy is standard treatment approach for patients with localized prostate cancer. Recently, Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat low/intermediate risk localized prostate cancer. However, there is relatively limited data regarding SABR +/- pelvic nodal irradiation in patients with high-risk disease.

(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussant presentation by Dr. Pilar Laguna from The Netherlands to discuss “Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST)” and “SEMS trial: Result of a prospective, multi-institutional phase II […]